Home / COVID-19 Coverage / URMC testing antiviral drug to treat COVID-19 patients

URMC testing antiviral drug to treat COVID-19 patients

1022557487_research-img-72dpi_5631_976x710The University of Rochester Medical Center announced today its participation in a clinical trial sponsored by the National Institute of Health to evaluate the safety and effectiveness of antiviral drug remdesivir for adult patients hospitalized with COVID-19.

Ann Falsey M.D. and Angela Branche M.D. lead the study alongside the URMC Vaccine Trials and Evaluation Unit (VTEU).

Remdesivir was developed by Gilead Sciences. It’s a broad-spectrum antiviral drug that has been tested in humans with the Ebola virus. Remdesivir has also been effective in treating illnesses caused by other coronaviruses like Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in animals.

The trial is double-blind and placebo-controlled. Acute COVID-19 patients at Strong Memorial Hospital will be used in the study. In the future, the study may grow to include other antiviral treatments that the VTEU wants to test.

nsheldon@bridgetowermedia.com / (585) 363-7031

Leave a Reply

Your email address will not be published.


Check Also

RW Dake Construction CEO Greg Vangellow (Provided photo)

As CEO, Vangellow is a vessel for continuing RW Dake’s reputation as a family business (access required)

As a commercial lender, it’s critical to understand the intricacies of accounting and finance. You’re not going to be of ...

Jacqueline Mozrall

Remote learning — Our continued evolution (access required)

Not too long ago, the thought of doing something online that could be done face-to-face was not generally desirable. Pre-pandemic, ...